Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. Annual Report: A Deep Dive for Investors

Welcome to your essential guide to Aquestive Therapeutics, Inc.'s performance over the most recent fiscal year. We'll cut through the jargon to give you a clear picture of what this company does, how it's performing, and what factors could influence your investment decisions.

Understanding Aquestive Therapeutics: Business & Performance

Aquestive Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative products. It primarily uses its proprietary PharmFilm® technology for drug delivery, focusing on areas like central nervous system (CNS) disorders and other critical care needs. The company's business model involves both developing its own proprietary products and leveraging its technology through partnerships for co-development and licensing.

Overall Performance: The past fiscal year saw Aquestive navigate significant clinical advancements alongside financial challenges. While the company continued to progress its pipeline and generate revenue from various sources, it operated at a net loss. This loss reflects ongoing investment in research and development, as well as costs associated with commercialization and legal matters.

Financial Performance: The Numbers That Matter

For the most recent fiscal year, Aquestive Therapeutics reported:

To fund its operations and growth initiatives, the company actively raised capital through "At-The-Market" (ATM) offerings and "Public Equity Offerings" (methods for selling shares to the public) in recent years. While these offerings provided crucial cash injections, they also significantly diluted existing shareholders.

Major Wins and Challenges

Wins:

• Clinical Progress: Aquestive advanced key pipeline candidates, reaching significant clinical or regulatory milestones during the year.
• Strategic Partnerships: The company formed or expanded collaborations to achieve specific development or commercialization goals.
• Capital Infusion: Successful equity raises provided essential funding to sustain operations and invest in future growth, securing the company's financial runway for the near term.

Challenges:

• Suboxone Product Liability Litigation: The company faces an ongoing, complex lawsuit related to Suboxone. This litigation, active recently, poses a substantial financial and reputational risk. Potential significant settlement costs or adverse judgments could materially impact the company's financial health.
• High Cash Burn Rate: Despite capital raises, the company's operational expenses, particularly R&D and SG&A, led to a substantial cash burn (rate of cash usage), requiring continuous capital management.
• Shareholder Dilution: Necessary equity offerings, while providing capital, diluted existing shareholders' ownership, potentially pressing the stock price.

Financial Health: Cash, Debt, and Liquidity

Aquestive Therapeutics' financial health features a significant debt load and relies on external financing.

• Debt Structure:
  • Senior Secured Notes: The company holds Senior Secured Notes with a high interest rate of 13.5%, maturing in November 2028. The annual interest expense on this debt is significant.
  • Royalty Obligations: It also carries unsecured Royalty Obligations, requiring ongoing payments based on product sales.
  • Previous Debt: The "Twelve Point Five Senior Secured Notes" matured in June 2025.
• Liquidity: Capital raised through equity offerings has bolstered the company's cash position, providing a liquidity runway to cover operational expenses and invest in its pipeline for the near term. However, the high interest burden on its debt significantly impacts free cash flow, making efficient capital allocation critical. The company's ability to continue operating (its "going concern" status) depends on securing additional financing and achieving profitable operations.

Key Risks That Could Impact Your Investment

Several significant risks could impact investors:

• Legal and Regulatory Risks: The ongoing Suboxone Product Liability Litigation is a primary concern. Its outcome is uncertain, and an unfavorable ruling or large settlement could deplete financial resources and damage the company's reputation. Additionally, the pharmaceutical industry is heavily regulated; delays or failures in obtaining FDA approvals for new drugs, or adverse regulatory changes, could significantly impact future revenue.
• Customer Concentration: A substantial portion of Aquestive's revenue and accounts receivable concentrates with a few key customers, notably Indivior and Haisco, and to a lesser extent, Cosmed and Hypera. Losing or significantly reducing business from any of these major customers could materially harm the company's financial results.
• High-Interest Debt Burden: The 13.5% interest rate on its Senior Secured Notes is exceptionally high, consuming a significant portion of operating cash flow. This limits financial flexibility and increases the risk of default if revenues do not grow as projected or if unexpected expenses arise.
• Share Dilution: The company's reliance on equity financing for growth means continued dilution for existing shareholders. While necessary for funding, this can depress stock price performance as its value spreads across more shares.
• Clinical Trial and Product Development Risk: Developing new drugs is inherently risky. Clinical trials can fail, products may not receive regulatory approval, or they may not achieve commercial success even if approved.
• Intellectual Property Protection: The company's success heavily relies on its proprietary PharmFilm® technology and product patents. Any challenges to its intellectual property, or the inability to protect it, could severely impact its competitive advantage.
• Competition: The pharmaceutical market is highly competitive. Aquestive faces competition from larger, more established companies with greater resources, as well as from generic manufacturers.

Competitive Positioning

Aquestive differentiates itself through its proprietary PharmFilm® technology, allowing for unique drug delivery methods that often improve patient adherence and convenience. This technology provides a competitive edge in specific therapeutic areas where traditional oral medications may be less effective or desirable. However, the company competes in markets with well-established players and must continually innovate and secure intellectual property to maintain its position. Successfully commercializing its pipeline products against established competitors will be crucial for its long-term success.

Leadership, Strategy, and Future Outlook

Leadership & Strategy: No major changes in executive leadership appeared, and the company's strategy remains focused on advancing its late-stage pipeline towards commercialization. It aims to leverage its PharmFilm® technology to address unmet medical needs and expand its product portfolio. Strategic partnerships are also a key component of its growth strategy, helping to share development costs and expand market reach.

Future Outlook: Aquestive's future hinges on several key factors:

• Successful Commercialization: The launch and market adoption of key pipeline candidates are critical for future revenue growth and profitability.
• Pipeline Advancement: Continued positive clinical trial results and regulatory approvals for other pipeline candidates are essential for long-term value creation.
• Resolution of Litigation: A favorable or manageable outcome in the Suboxone litigation would remove a significant financial and stock burden.
• Capital Management: The company must continue managing its cash burn and potentially seek further financing, balancing capital needs with shareholder dilution.
• Market Trends & Regulatory Changes: Broader pharmaceutical market trends, including increasing demand for patient-friendly drug delivery systems and evolving regulatory landscapes, will continue to influence Aquestive. Changes in healthcare policy, drug pricing regulations, or shifts in treatment paradigms could impact its commercial prospects.

In summary, Aquestive Therapeutics is a company with innovative technology and a promising pipeline. However, it operates in a high-risk, high-reward environment characterized by significant debt, ongoing litigation, and a need for substantial capital investment to realize its full potential.